![]() |
市場調查報告書
商品編碼
2008776
嬰兒癲癇治療市場:按藥物類別、藥物類型、劑量、給藥途徑、分銷管道、最終用戶和地區分類(2026-2034 年)Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2026-2034 |
||||||
2025年,全球嬰幼兒癲癇治療市場規模達39億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到53億美元,2026年至2034年的複合年成長率(CAGR)為3.38%。推動市場成長的主要因素包括嬰幼兒癲癇發病率的上升、公眾健康意識的提高促進了早期診斷,以及越來越多的產品核可和強大的在研藥物儲備。
嬰兒癲癇治療是指用於治療嬰幼兒(通常為4個月至1歲)癲癇發作和癲癇症候群的治療方法。癲癇發作的特徵是身體突然僵硬,手臂、腿部和頭部向前彎曲,背部弓起,這些症狀以短暫的、微小的發作形式出現。嬰兒癲癇的病因包括腦腫瘤、出生創傷、腦部感染疾病和基因突變。目前有多種治療嬰兒癲癇的方法,包括使用類固醇、促皮質素注射或糖皮質激素進行荷爾蒙療法以及抗驚厥藥物。如果在癲癇發作後3週內開始治療,嬰兒癲癇的療效會更好,治療可採用單藥治療或聯合治療。嬰兒癲癇的診斷包括身體檢查、神經系統檢查、腦部MRI以及血液和尿液檢查。
新生兒癲癇發生率的不斷上升是推動市場成長的關鍵因素。這主要歸因於全球出生率的顯著成長。因此,產品核可的增加和強大的在研藥物儲備正在對市場產生正面影響。治療新生兒癲癇的持續技術進步,例如癲癇發作預警裝置的引入(該裝置能夠檢測癲癇發作並提醒看護者),正在促進市場發展。此外,人們對早期診斷和治療的認知不斷提高,提高了新生兒癲癇藥物的普及率,從而刺激了市場成長。然而,包括治療成功率低、治療費用高、嚴格的藥物核准法規以及未確診患者數量不斷增加在內的各種因素,正在阻礙新生兒癲癇藥物市場的成長。另一方面,一些國家政府和私營機構實施的旨在提高公眾對該疾病認知的有益舉措和項目,為市場帶來了良好的前景。此外,主要市場參與者進行的大量研發活動,專注於開發成功率更高的創新藥物,也正在推動市場成長。推動市場成長的其他因素包括醫療保健支出增加、合作與夥伴關係併購增加、都市化加快以及可支配收入水準上升。
The global infantile spasms therapeutics market size reached USD 3.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2026-2034. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.
Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures . Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.
The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.
The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.